Back to Awarded Treatment Trials
Awarded Trial: 04T-504
Grant ID
04T-504
Illness
Schizophrenia
Primary Drug/Intervention
Raloxifene
Primary Dosage
60mg/day
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Usall-Rodie
Sample Size
36
Duration of Study Period for Each Subject
12 weeks
Outcome Measurements
SCID, PANSS, CGI, Calgary Depression Scale, Simpson Scale, GAF, Living Skills Profile
Results
Thirty-three (33) postmenopausal women with schizophrenia and prominent negative symptoms were randomized to adjunct raloxifene 60 mg or placebo for 3 months. Those on raloxifene had a significant reduction in both negative (p=0.04), positive (p=0.03), and general pathological (p=0.05) symptoms.
Publication
Usall J, Huerta-Ramos E, Labad J, Cobo J, Núñez C, Creus M, Parés GG, Cuadras D, Franco J, Miquel E, Reyes JC, Roca M; RALOPSYCAT Group. Raloxifene as an Adjunctive Treatment for Postmenopausal Women with Schizophrenia: A Double-Blind, Randomized, Placebo-Controlled Trial. J Clin Psychiatry. 2001;72(11):1552-1557.
Link
http://www.ncbi.nlm.nih.gov/pubmed/26591005
PI Name
Judith Usall-Rodie
Degree
MD
Center
San Joan de Deu-Serveis de Salut Mental
Institution
Fundacio Sant Joan de Deu
Address
c/ Santa Rosa 39-57, 4 planta
City or Town
Esplugues de Ll,
State or Province
Barcelona
Zip or Postal Code
8950
Country
Spain
Email Address
jusall@sjd-ssm.com